Loading...
OTCM
WXIBF
Market cap21bUSD
Oct 06, Last price  
5.60USD
1D
-0.18%
1Q
76.10%
IPO
-18.84%
Name

WuXi Biologics (Cayman) Inc

Chart & Performance

D1W1MN
No data to show
P/E
48.33
P/S
8.68
EPS
0.82
Div Yield, %
—
Shrs. gr., 5y
1.13%
Rev. gr., 5y
36.21%
Revenues
18.68b
+9.63%
331,850,000557,042,000989,029,0001,618,829,0002,534,453,0003,983,687,0005,612,384,00010,290,050,00015,268,660,00017,034,255,00018,675,371,000
Net income
3.36b
-1.28%
41,978,00044,509,000141,096,000252,628,000630,592,0001,013,805,0001,688,886,0003,388,478,0004,420,286,0003,399,729,0003,356,081,000
CFO
5.22b
+11.77%
21,505,000107,150,00081,921,000360,280,000761,607,0001,208,079,0001,881,276,0003,431,258,0005,541,673,0004,667,712,0005,217,257,000

Profile

WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.
URL
https://www.wuxibiologics.com/
IPO date
Jun 13, 2017
Employees
12,397
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
18,675,371
9.63%
17,034,255
11.56%
15,268,660
48.38%
Cost of revenue
13,938,109
12,788,292
10,659,969
Unusual Expense (Income)
NOPBT
4,737,262
4,245,963
4,608,691
NOPBT Margin
25.37%
24.93%
30.18%
Operating Taxes
889,027
603,179
807,865
Tax Rate
18.77%
14.21%
17.53%
NOPAT
3,848,235
3,642,784
3,800,826
Net income
3,356,081
-1.28%
3,399,729
-23.09%
4,420,286
30.45%
Dividends
Dividend yield
Proceeds from repurchase of equity
(1,746,554)
(890,758)
(2,768,274)
BB yield
2.35%
0.69%
1.06%
Debt
Debt current
2,619,006
731,308
1,470,488
Long-term debt
4,624,492
6,244,036
4,589,841
Deferred revenue
460,466
969,233
949,462
Other long-term liabilities
Net debt
(3,435,509)
(7,202,379)
(3,044,104)
Cash flow
Cash from operating activities
5,217,257
4,667,712
5,541,673
CAPEX
(3,929,621)
(4,045,574)
(5,868,390)
Cash from investing activities
(3,941,706)
(3,228,266)
(5,908,252)
Cash from financing activities
(2,750,191)
1,961,163
(2,591,592)
FCF
1,526,050
(213,837)
(2,932,842)
Balance
Cash
10,709,791
11,243,437
8,714,323
Long term investments
(30,784)
2,934,286
390,110
Excess cash
9,745,238
13,326,010
8,341,000
Stockholders' equity
20,014,524
21,938,243
14,111,051
Invested Capital
41,132,646
36,222,464
32,411,869
ROIC
9.95%
10.62%
12.36%
ROCE
9.29%
8.55%
11.27%
EV
Common stock shares outstanding
4,227,165
4,348,874
4,375,908
Price
17.56
-40.68%
29.60
-50.54%
59.85
-35.33%
Market cap
74,229,010
-42.34%
128,726,685
-50.85%
261,898,079
-36.00%
EV
74,451,861
126,702,667
260,019,645
EBITDA
6,174,316
5,415,339
5,409,365
EV/EBITDA
12.06
23.40
48.07
Interest
157,587
158,488
64,382
Interest/NOPBT
3.33%
3.73%
1.40%